Tasly Pharmaceutical Gets Registration Certificate for Osteoarthritis Treatment Capsules

Tasly Pharmaceutical's attributable profit rose 6.5% to 314.3 million yuan in the first quarter from 295.2 million yuan in the year-ago period, according to a Tuesday filing with the Shanghai bourse.

Earnings per share at the drug company increased 6.5% to 0.2104 yuan from 0.1976 yuan in the year-ago period.

Operating income inched up 0.3% to 2.05 billion, the filing said.

China's National Medical Products Administration approved Tasly Pharmaceutical's application to conduct clinical trials on a drug for recurrent glioblastoma, according to a Shanghai Stock Exchange filing on Saturday.

The P134 cell injection, which was developed by the pharmaceutical company and the Beijing Neurosurgical Institute, will undergo phase 1 trials for patients with the condition.

The pharmaceutical company invested 49.6 million yuan into the research and development of the drug, the filing said.

China has granted Tasly Pharmaceutical clinical trial approval for its allogeneic adipose-derived mesenchymal stromal cell injection for acute ischemic stroke, according to a Friday filing with the Shanghai Stock Exchange.

The drug activates vascular regeneration and functional repair of damaged brain tissue in stroke patients, the filing said.

Tasly's injection has also been approved for clinical trial in the US in October 2024, the filing said.

Tasly Pharmaceutical's attributable profit fell 11% to 1.04 billion yuan in 2024 from 1.18 billion yuan in the year-ago period, according to a Tuesday filing with the Shanghai Stock Exchange.

Earnings per share at the drug company decreased 11% to 0.64 yuan from 0.72 yuan in the previous year.

Operating income declined 2% to 8.50 billion yuan from 8.67 billion yuan a year earlier.

Shares slid 3% during Tuesday's morning trading.